The FAST Program provides select entrepreneurs with intensive team review and coaching to perfect their business model, product development plans, and to build a compelling commercialization strategy. Emerging innovators benefit from the advice and counsel of industry veterans – custom-selected from the FAST network of over 425 professionals comprised of entrepreneurs, product, and business experts (i.e., clinical development, regulatory, reimbursement, and business development specialists) – during the twelve-week program. The program culminates with a Final FAST Showcase and Reception where FAST companies present to a distinguished audience of potential investors and collaboration partners.

Application to the FAST program is on a rolling basis.

Apply For the FAST Program

Our Impact

Fall FAST 2022 Companies

  • Acelot | Acelot is an early stage biotechnology startup developing small molecules that inhibitmultiple toxic protein species associated with neurodegenerative diseases
  • Angeles Therapeutics | Angeles Therapeutics is a next generation cell therapy company. Angelesis confident that with its next generation CAR design, it has solved the problem of lack of efficacy of CARs in solid tumors
  • BioMark Oncology | BioMark Oncology is a translationally enabled, preclinical-stage pharmaceutical company developing a platform to further the use of response biomarkers in clinical trials.
  • TAB Diagnostics | Tab Diagnostics is a non-invasive diabetes testing and monitoring company developing the first portable saliva-based, graphene field-effect transistor assay to measure Glycated Albumin (diabetic biomarker).
  • Weatherwax | Weatherwax Biotechnologies is a seed-stage startup developing the next generation of induced-proximity medicines.

View portfolio of past FAST companies

Spring FAST 2022 Companies

  • Cache DNA | Cache DNA is building a biologically-inspired operating system to store and compute biomolecules at unprecedented scales.
  • Cellular Vehicles | Cellular Vehicles is creating hardware to Enable the Next-Generation of Cell Therapy Treatments
  • Glyphic Bio | Glyphic Biotechnologies is developing a single-molecule next-generation protein sequencer to enable the development of novel therapeutics and diagnostics.
  • Hopo Therapeutics | HOPO Therapeutics develops best-in-class, orally available small molecule therapies to prevent and treat lead poisoning and other unmet needs in global women’s and children’s health.
  • Loxagen | Loxagen was started by industry and research veterans to target the family of Lipoxygenases involved in the pathogenesis of oncology, metabolic and CNS disease.
  • MabSwitch | MabSwitch, Inc is a biotechnology company that aims to develop in-vivo regulatable next generation antibody immunotherapies based on a proprietary universal allosteric switch module for antibodies(UNASMA) technology platform, to address diseases of significant unmet medical need.

View portfolio of past FAST companies

FAST Expansion

Servier Discovery Award:  Companies and academia who are developing innovative therapeutic approaches in the following disease areas of oncology; auto-immune diseases; and genetically driven neurodegenerative and movement disorders are encouraged applied for the new Servier Discovery Award. The winner will be selected to participate in the CLS FAST Fall cohort—a program that matches entrepreneurs with a custom team of advisors for intensive team review.

MESH Academy at the Keck School of Medicine of USC: A new dedicated FAST-USC MESH track will bring FAST advisory services to entrepreneurs from USC as part of CLS’ expansion of the FAST program to Southern California. The FAST-USC MESH track will serve two USC faculty-led startups annually, providing them with about $25 thousand of pro bono advisory services.

CLS Inspire QuickFire Challenge for BIPOC Communities: California-based innovators are invited to submit potential solutions for BIPOC communities which have been historically marginalized. The innovator(s) with the best potential solution will receive grant funding from a total pool of $150,000, one year of complimentary CLS membership to allow awardees visibility through CLS events and programs and access to new and existing collaboration partners. One awardee will be invited to participate in the 2023 Spring FAST Program, receiving commercialization advising from a tailored group of industry veterans.

FAST MedTechColor Track: CLS supports the MedTech Color Pitch Competition which sends select winners of both through the FAST program—growing the pool of diverse life sciences startups in the FAST community.

WIB-FAST Advisory Program: The WIB-FAST program is open to early-stage female (co-)founders of pre-revenue life sciences companies who are developing highly innovative technologies that will have a meaningful impact on human or environmental health. WIB-FAST is designed to help women entrepreneurs who seek advising on raising capital (Angel, Seed or Series A), commercialization or business plans, and legal or scientific strategy.

Supported By:

Platinum Sponsors

Gold Sponsors

Interested in Learning More?

Sibylle Hauser
Executive Director, Innovation Services
[email protected]